AbCellera Biologics reports Monday with an unusually charged setup: 15% short interest, a stock that just surged 21% in a week, and two analyst target raises filed the morning after the last quarterly print.
Short sellers are heavily committed here. At 15.2% of the free float — roughly 45.5 million shares — short interest is well above what would typically be considered incidental. It has been broadly stable over the past month, ticking up just over 2%, suggesting bears have not been spooked by the recent price rally. That rally is sharp: ABCL closed Friday at $6.93, up 6% on the day and 21% over the past week, though still 10% below where it traded a month ago. The ORTEX short score has crept higher through this move, reaching 77 — a reading that flags elevated crowding pressure regardless of which direction the stock eventually breaks. Borrow availability has loosened materially, nearly tripling over the past week to 83%, suggesting the lending market is not yet tight enough to threaten a mechanically forced squeeze. Cost to borrow, running around 6%, is elevated but not extreme.
Analyst sentiment has shifted visibly in the right direction. Stifel raised its target from $8 to $9 and Cantor Fitzgerald moved from $11 to $12, both actions filed August 6 while maintaining Buy and Overweight ratings respectively. A Benchmark upgrade to Buy in early July added further momentum to the constructive camp. The consensus mean target of $10.63 implies roughly 53% upside from current levels — a wide gap that frames the bull case: AbCellera's antibody discovery platform carries more than 20 active programs, recent Jazz and Vertex partnerships provide near-term cash, and the company is advancing two drug candidates through clinical development. Bears counter that the pipeline lacks disclosed detail, clinical data timelines are long, and the business has yet to generate meaningful recurring revenue. The stock's negative earnings yield and deeply negative EV/EBITDA confirm this is still a pre-profitability story priced entirely on platform optionality.
The ownership structure adds an interesting dimension. CEO and founder Carl Hansen holds nearly 19% of shares and has bought stock on the open market repeatedly — including $710,000 of purchases in February 2026 at prices around $3.30-$3.44. Baker Bros., the specialist biotech fund, holds just under 10% and added 28 million shares in the most recent reporting period, a dramatic build that represents a major conviction bet. Insider buying alongside that kind of institutional accumulation, at prices well below today's levels, creates a natural floor of long-term holders who are not likely to be shaken by a volatile print. The five-day reaction after the June quarter was a gain of 8.6%, following a 7.2% one-day pop after last quarter's August release — ABCL has a recent pattern of rewarding the post-print move, at least in the short run.
Monday's print will test whether the platform partnerships are translating into durable revenue momentum — and whether a 21% weekly run leaves any room for disappointment at a stock where 15% of the float is still betting against it.
See the live data behind this article on ORTEX.
Open ABCL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
